Dancann Pharma

This legislative milestone confirms Denmark’s commitment to a long-term, structured integration of cannabinoid-based medicines into the national healthcare system. Bill L135 was adopted with 101 votes in favour and 10 votes against.

“We welcome this decision by the Danish Parliament and view it as a regulatory confirmation of the significant role that medicinal cannabis can and should play in patient care going forward,” says Jeppe Krog Rasmussen, CEO of DanCann Pharma A/S.

The new law enhances regulatory clarity, ensures continued access for patients under medical supervision, and provides a stable foundation for companies like DanCann Pharma to further invest, develop, and operate within a compliant framework.

Key implications for DanCann Pharma A/S:

• A permanent legal basis for commercial activities for distribution of medicinal cannabis in Denmark
• Reinforcement of Denmark’s position as a first mover within Scandinavia in cannabinoid-based therapies
• Enables long-term business planning, investment, and international partnerships

DanCann Pharma welcomes the opportunity to further collaborate with authorities, healthcare professionals, and industry partners under the new legislative structure.

For more information, please see: Danish Parliament Voting Record – Bill L135.

For further information, please contact:

Jeppe Krog Rasmussen,

Chief Executive Officer

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, please visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.